HCG Share Price Performance
₹615.80
261.35 (73.73%)
1.9% undervalued intrinsic discount
₹628.00
Fair Value
Price ₹615.80
AnalystHighTarget ₹628.00
AnalystConsensusTarget ₹603.88
AnalystLowTarget ₹379.53
Fair Value₹628.00
Share Price₹615.80
1.9% undervalued intrinsic discount
HCG Community Narratives
AN
Fair Value ₹628.00 1.9% undervalued intrinsic discount
Rising Indian NCD Burden And Urbanization Will Transform Oncology Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹603.88 2.0% overvalued intrinsic discount
KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value ₹379.53 62.3% overvalued intrinsic discount
Rising Costs And Complexities Will Weaken Indian Oncology Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
HCG Community Fair Values
- ₹603.88FV2.0% overvalued intrinsic discount13.37%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative5users have followed this narrativeUpdated narrative
- ₹379.53FV62.3% overvalued intrinsic discount14.62%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative13 days ago author updated this narrative
- ₹628.00FV1.9% undervalued intrinsic discount14.62%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative13 days ago author updated this narrative
Recent HCG News & Updates
No updates
HealthCare Global Enterprises Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 2.66
- Gross Margin
- 36.03%
- Net Profit Margin
- 1.60%
- Debt/Equity Ratio
- 185.6%
HealthCare Global Enterprises Limited Competitors
About HCG
- Founded
- 1989
- Employees
- 6150
- CEO
- WebsiteView website
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand that provides inpatient and outpatients treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. In addition, the company offers cancer diagnostic services; combining laboratory services; and research and development, and clinical research to enhance cancer diagnosis and prognosis. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Indian Market Performance
- 7 Days: -0.8%
- 3 Months: 4.5%
- 1 Year: -2.1%
- Year to Date: -1.3%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. In line with that, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading